Tempest Therapeutics has achieved a crucial manufacturing milestone by delivering the TPST-2003 lentiviral vector to its partner Cincinnati Children’s AGCTC, enabling production for a pivotal clinical trial of its dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma. This follows positive interim trial data showing a 100% complete response rate in evaluable patients, supporting an accelerated development timeline. Tempest plans to start a potentially registrational study in Q4 2026 and will present updated clinical results later this year, aiming to offer a new treatment option for difficult-to-treat multiple myeloma cases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
